Meronem Injection Powder is a systemic antimicrobial. It is recommended in the treatment of pneumonia, acute bacterial meningitis, infections and inflammatory processes in the genitourinary system, on the skin and in soft tissues, abdominal organs. Read more about the dosage and application features in the instructions.
Indications for use (instruction): Meronem
Meronem is indicated for the treatment of such infections in adults and children from the age of 3 months:
- pneumonia, including community-acquired and hospital pneumonia;
- bronchopulmonary infections with cystic fibrosis;
- complicated urinary tract infections;
- complicated intra-abdominal infections;
- infections during childbirth and postpartum infections;
- complicated infections of the skin and soft tissues;
- acute bacterial meningitis.
Meronem can be used to treat patients with neutropenia and fever if it is suspected to be caused by a bacterial infection.
Treatment of patients with bacteremia that is associated with or may be associated with any of the above infections.
Formal recommendations regarding the appropriate use of antibacterial drugs should be considered.
How to use
Read more about dosage in the instructions.
Mode of application
Meronem should usually be used as an infusion lasting 15 to 30 minutes. Alternatively, doses of meropenem up to 20 mg/kg may be administered as a bolus injection within 5 minutes. Safety data confirming the administration of the drug at a dose of 40 mg / kg to children as a bolus injection is limited.
A bolus injection solution should be prepared by dissolving the Meronem drug in water for injection to a concentration of 50 mg/ml.
The chemical and physical stability of the prepared solution for bolus injection was demonstrated for 3 hours at a temperature of 25 °C or 12 hours in a refrigerator (2–8 °C).
From a microbiological point of view, if the discovery/restoration/dilution method does NOT exclude the risk of microbiological contamination, the drug should be used immediately.
If the drug is not immediately used, the terms and conditions of storage of the prepared solution should be carefully monitored.
An infusion solution should be prepared by dissolving the Meronem drug in a 0.9% solution of sodium chloride for injection or in a 5% solution of glucose (dextrose) for injection in a concentration of 1–20 mg/ml.
The chemical and physical stability of the prepared solution for infusion with the introduction of a 0.9% sodium chloride solution was demonstrated for 3 hours at a temperature of 25 °C or for 24 hours in a refrigerator (2–8 °C). From a microbiological point of view, the drug must be used immediately. If the drug is not immediately used, the terms and conditions of storage of the prepared solution should be carefully monitored.
Prepared with 5% glucose (dextrose) solution, Meronem should be used immediately.
Cooked solutions should not be frozen.
Hypersensitivity to the active substance or to any of the drug excipients.
Hypersensitivity to any other antibacterial agent of the carbapenem group.
Severe hypersensitivity (e.g. anaphylactic reactions, severe skin reactions) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).
Active substance: meropenem;
1 vial contains: meropenem trihydrate 570 mg (equivalent to 500 mg anhydrous meropenem) or meropenem trihydrate 1140 mg (equivalent to 1000 mg anhydrous meropenem).
Excipients: sodium carbonate anhydrous.
Packaging. Glass bottles closed with a rubber stopper and sealed with an aluminum cap. 10 vials in a cardboard box.
Dosage form. Powder for solution for injection.
Basic physical and chemical properties: powder from white to light yellow.
Store at a temperature not exceeding 30 °C. Do not freeze. Keep out of the reach of children.
Each vial is for single use only.
When preparing the solution and during its use, standard aseptic working methods should be used.
Shake the solution before use.
Any unused product or waste must be disposed of in accordance with local regulations.
AstraZeneca UK Лімітед, Silk Road Business Park, Macclesfield, SК10 2NA, United Кінґдом.
Sanitary and hygienic conclusion
No. 1212 dated 05/30/2019.
Registration Certificate No. UA/0186/01/02.
This section of the site contains information about medicines, their properties, methods of use, as well as other specialized information that is intended for healthcare professionals. The information on medicines contained in this section is not a guide for self-diagnosis and / or treatment. LLC SA Pro-Pharma is not responsible for possible negative consequences arising from the independent use of information from this section. Using the information from this section, you do it yourself, understanding that: self-medication can be harmful to your health, you must read the instructions and consult a doctor before using medicines.